Expression of Senescence and Apoptosis Biomarkers in Synchronous Bilateral Breast Cancer: A Case Report.
BCL-2
apoptosis
bilateral
breast cancer
chemotherapy
p16INK4a
senescence
synchronous
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
31
08
2021
accepted:
28
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
28
10
2021
Statut:
epublish
Résumé
Synchronous bilateral breast cancer (SBBC) provides a special condition where two independent breast tumors are exposed to cancer pharmacotherapy within a uniform pharmacokinetic milieu. Both senescence and apoptosis are established responses to therapy; however, they have potentially variable contributions to the overall outcome of treatment, which are yet to be determined. In this report, we describe the clinicopathological picture of two SBBC cases that received standard anticancer treatment and assess their expression profile of several molecular hallmarks of senescence and apoptosis. Our analysis identified that synchronous tumors have variable expression profiles of both senescence- and apoptosis-associated biomarkers, despite comparable pathological responses to neoadjuvant chemotherapy and current survival rates. Our results highlight the variable expression of senescence- and apoptosis-associated markers in breast tumors (despite the shared somatic genetic background) and invites a large-scale assessment of both senescence and apoptosis in breast cancer tissue in vivo and their contribution to the pathological response and overall survival.
Sections du résumé
BACKGROUND
Synchronous bilateral breast cancer (SBBC) provides a special condition where two independent breast tumors are exposed to cancer pharmacotherapy within a uniform pharmacokinetic milieu. Both senescence and apoptosis are established responses to therapy; however, they have potentially variable contributions to the overall outcome of treatment, which are yet to be determined.
METHODS
In this report, we describe the clinicopathological picture of two SBBC cases that received standard anticancer treatment and assess their expression profile of several molecular hallmarks of senescence and apoptosis.
RESULTS
Our analysis identified that synchronous tumors have variable expression profiles of both senescence- and apoptosis-associated biomarkers, despite comparable pathological responses to neoadjuvant chemotherapy and current survival rates.
CONCLUSIONS
Our results highlight the variable expression of senescence- and apoptosis-associated markers in breast tumors (despite the shared somatic genetic background) and invites a large-scale assessment of both senescence and apoptosis in breast cancer tissue in vivo and their contribution to the pathological response and overall survival.
Identifiants
pubmed: 34677245
pii: curroncol28050327
doi: 10.3390/curroncol28050327
pmc: PMC8535022
doi:
Substances chimiques
Biomarkers
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3836-3845Références
PLoS One. 2014 Apr 15;9(4):e95185
pubmed: 24736632
Exp Cell Res. 2000 Apr 10;256(1):42-9
pubmed: 10739650
Front Oncol. 2020 Feb 11;10:27
pubmed: 32117708
Cell Death Differ. 2015 Jul;22(7):1071-80
pubmed: 25952548
Breast Cancer Res Treat. 2020 Jul;182(1):229-238
pubmed: 32441019
Cell Death Differ. 2020 Nov;27(11):3097-3116
pubmed: 32457483
Biomed Res Int. 2014;2014:150845
pubmed: 25013758
Mol Oncol. 2020 Oct;14(10):2504-2519
pubmed: 32652830
Cancers (Basel). 2021 Jan 21;13(3):
pubmed: 33494434
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848
pubmed: 32046998
J Biol Chem. 2011 Apr 15;286(15):12825-38
pubmed: 21292770
Br J Surg. 2009 Apr;96(4):376-80
pubmed: 19283743
Gynecol Obstet Fertil. 2008 Jan;36(1):35-44
pubmed: 18178120
Cell Death Differ. 2007 May;14(5):1020-8
pubmed: 17290286
Cancers (Basel). 2020 Mar 29;12(4):
pubmed: 32235364
Breast Cancer Res Treat. 2014 Aug;146(3):461-75
pubmed: 25007962
Rep Pract Oncol Radiother. 2018 Sep-Oct;23(5):322-330
pubmed: 30127671
Histol Histopathol. 2018 Jan;33(1):55-64
pubmed: 28276034
J Clin Diagn Res. 2015 Sep;9(9):XC05-XC08
pubmed: 26500995
Trends Cell Biol. 2018 Jun;28(6):436-453
pubmed: 29477613
Biosci Rep. 2021 May 28;41(5):
pubmed: 33948615
Cell Death Dis. 2018 Jan 16;9(2):19
pubmed: 29339815
Breast. 2011 Apr;20(2):158-64
pubmed: 21093260
Nat Med. 2016 Jan;22(1):78-83
pubmed: 26657143
Breast Dis. 2020;39(2):51-59
pubmed: 31839602
Br J Cancer. 2019 Apr;120(7):761-767
pubmed: 30804429
Aging Cell. 2016 Jun;15(3):428-35
pubmed: 26711051
J Am Geriatr Soc. 2017 Oct;65(10):2297-2301
pubmed: 28869295
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2766-71
pubmed: 21768359
Asian Pac J Cancer Prev. 2015;16(3):1007-10
pubmed: 25735321